Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Deferred Tax (2021 - 2025)

Historic Long-Term Deferred Tax for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $285.0 million.

  • Indivior Pharmaceuticals' Long-Term Deferred Tax fell 625.0% to $285.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $285.0 million, marking a year-over-year decrease of 625.0%. This contributed to the annual value of $277.0 million for FY2024, which is 314.69% down from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Long-Term Deferred Tax stood at $285.0 million, which was down 625.0% from $270.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Long-Term Deferred Tax registered a high of $304.0 million during Q3 2024, and its lowest value of $105.0 million during Q4 2021.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $273.5 million (2024), whereas its average is $253.1 million.
  • In the last 5 years, Indivior Pharmaceuticals' Long-Term Deferred Tax soared by 10857.14% in 2022 and then tumbled by 689.66% in 2025.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Long-Term Deferred Tax stood at $105.0 million in 2021, then soared by 108.57% to $219.0 million in 2022, then skyrocketed by 30.59% to $286.0 million in 2023, then fell by 3.15% to $277.0 million in 2024, then increased by 2.89% to $285.0 million in 2025.
  • Its Long-Term Deferred Tax was $285.0 million in Q3 2025, compared to $270.0 million in Q2 2025 and $279.0 million in Q1 2025.